Can a vaccine stop stomach cancer from coming back?
NCT ID NCT05771584
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a therapeutic cancer vaccine called AST-301 can safely train the immune system to fight HER2-expressing gastric cancer cells. The study enrolls people with stage II or III gastric cancer who have already had surgery and completed standard adjuvant treatment. Participants receive the vaccine plus an immune booster in either 3 or 6 doses, and researchers will monitor for side effects and immune responses, as well as how long participants remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a therapeutic cancer vaccine called AST-301 (pNGVL3-hICD) plus an immune booster (sargramostim)
- What this could lead to
- If successful, this vaccine could train the immune system to recognize and destroy leftover cancer cells, potentially preventing gastric cancer from coming back after surgery and standard therapy.
- What could go wrong
- This is an early proof-of-concept trial with only 24 participants, so results may not apply broadly. The vaccine may cause side effects or fail to trigger a strong enough immune response to prevent recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital Linkou
Taoyuan, 333, Taiwan
-
Chi Mei Medical Center
Tainan, 710, Taiwan
-
China Medical University Hospital
Taichung, 404, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 112, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a new nucleotide analogue boost cancer treatment?
- Can a less extensive stomach surgery preserve appetite better?
- New imaging compound targets Hard-to-Spot cancers
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Smart T-Cell engager aims to outsmart tumors in first human test